Telix hosts webinar on theranostics for glioma and glioblastoma
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address these.
David N. Cade, MD, Telix Group Chief Medical Officer will provide a clinical update, which will be followed by a fireside chat with Nelleke Tolboom, MD, Nuclear Medicine physician and academic faculty member at UMC Utrecht (Netherlands) and Josef Pichler, MD, Head of the Neuro-oncological Center at Kepler University Hospital Linz (Austria).
The presentation will be followed by Q&A with Dr. Cade and Richard Valeix, CEO, Telix Therapeutics.
Webinar date and time:
EDT: Monday, June 29, 2026, 5:00 p.m.
AEST: Tuesday, June 30, 2026, 7:00 a.m.
Participants can register for the webinar at the following link:
https://s1.c-conf.com/diamondpass/10054826-mur5i9.html
What the stars mean:
★ Poor ★ ★ Promising ★★★ Good ★★★★ Very good ★★★★★ Exceptional
Tag:
Related Contents
Latest News
More News
- DFI debuts Industrial Edge AI platforms at Automate 2026 (June 23, 2026 | 16:36)
- Sisram Medical expands EBD and injectables in Thailand for APAC growth (June 23, 2026 | 16:33)
- Electrolux rights issue oversubscribed, final outcome announced (June 23, 2026 | 16:31)
- Abu Dhabi DoH and Sanofi sign MOU to advance vaccine innovation (June 23, 2026 | 15:40)
- Canadian Solar launches TOPCon 3.0 module with 670 Wp output (June 23, 2026 | 15:06)
- AI cuts Changzhou power connection planning from days to minutes (June 23, 2026 | 12:03)
- IBM and OpenAI deploy frontier AI to counter machine-speed cyber threats (June 23, 2026 | 12:00)
- CARsgen wins world-first CAR T-cell approval for solid tumours (June 23, 2026 | 11:56)
Latest News
Mobile Version